Longterm (52-week) results of a phase III randomized, controlled trial of apremilast in patients with psoriatic arthritis

Journal of Rheumatology

Volumn 42, Issue 3, 2015, Pages 479-488

  Kavanaugh, Arthur ^a   Mease, Philip J ^b   Gomez Reino, Juan J ^e   Adebajo, Adewale O ^d   Wollenhaupt, Jürgen ^f   Gladman, Dafna D ^h   Hochfeld, Marla ^c   Teng, Lichen L ^c   Schett, Georg ^g   Lespessailles, Eric ⁱ   Hall, Stephen ^j  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c CELGENE CORPORATION   (United States)

^d UNIVERSITY OF SHEFFIELD   (United Kingdom)

^e University Hospital of Santiago de Compostela   (Spain)

^f Klinik für Rheumatologie Handchirurgie Rheumazentrum Oberammergau   (Germany)

^g UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^h UNIVERSITY HEALTH NETWORK   (Canada)

ⁱ UNIVERSITÉ D'ORLÉANS   (France)

^j MONASH UNIVERSITY   (Australia)

more..

Author keywords

Apremilast; Phosphodiesterase 4 inhibitor; Psoriatic arthritis; Safety; Treatment efficacy

Indexed keywords

APREMILAST; C REACTIVE PROTEIN; CREATININE; LEFLUNOMIDE; METHOTREXATE; PLACEBO; PREDNISONE; SALAZOSULFAPYRIDINE; NONSTEROID ANTIINFLAMMATORY AGENT; PHOSPHODIESTERASE IV INHIBITOR; THALIDOMIDE;

ABNORMAL LABORATORY RESULT; ABNORMAL THINKING; ACUTE HEART INFARCTION; ADULT; APPENDICITIS; ARTICLE; CLOSTRIDIUM INFECTION; CONTROLLED STUDY; DACTYLITIS; DEEP VEIN THROMBOSIS; DIARRHEA; DISEASE ACTIVITY; DISEASE SEVERITY; DRUG EFFICACY; DRUG FATALITY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENDOMETRIOSIS; FEMALE; FUNCTIONAL ASSESSMENT; GASTROENTERITIS; HEADACHE; HEALTH ASSESSMENT QUESTIONNAIRE; HEALTH ASSESSMENT QUESTIONNAIRE DISABILITY INDEX; HEMOGLOBINOPATHY; HUMAN; HYPERTENSIVE CRISIS; HYPERTRANSAMINASEMIA; HYPOTENSION; INCIDENCE; MAJOR CLINICAL STUDY; MALE; NAUSEA; OSTEOARTHRITIS; PAIN ASSESSMENT; PHASE 3 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; PROSTATE CANCER; PSORIASIS; PSORIATIC ARTHRITIS; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SHORT FORM 36; SIDE EFFECT; SKIN CARCINOMA; SYMPTOMATOLOGY; UPPER RESPIRATORY TRACT INFECTION; WEIGHT REDUCTION; AGED; ANALOGS AND DERIVATIVES; ARTHRITIS, PSORIATIC; CLINICAL TRIAL; DOUBLE BLIND PROCEDURE; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

ADULT; AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ARTHRITIS, PSORIATIC; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; PHOSPHODIESTERASE 4 INHIBITORS; SEVERITY OF ILLNESS INDEX; THALIDOMIDE; TREATMENT OUTCOME;

EID: 84923863943     PISSN: 0315162X     EISSN: 14992752     Source Type: Journal    
DOI: 10.3899/jrheum.140647     Document Type: Article

References (13)

1. Schafer P. Apremilast mechanism of action and application to psoriasis and psoriatic arthritis. Biochem Pharmacol 2012;83:1583-90.
2. Kavanaugh A, Mease PJ, Gomez-Reino JJ, Adebajo AO, Wollenhaupt J, Gladman DD, et al. Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor. Ann Rheum Dis 2014;73:1020-6.
3. Gladman DD, Antoni C, Mease P, Clegg DO, Nash P. Psoriatic arthritis: epidemiology, clinical features, course, and outcome. Ann Rheum Dis 2005;64 Suppl 2:ii14-7.
4. Strand V, Sharp V, Koenig AS, Park G, Shi Y, Wang B, et al. Comparison of health-related quality of life in rheumatoid arthritis, psoriatic arthritis and psoriasis and effects of etanercept treatment. Ann Rheum Dis 2012;71:1143-50.
5. Singh JA, Strand V. Spondyloarthritis is associated with poor function and physical health-related quality of life. J Rheumatol 2009;36:1012-20.
6. Zhu TY, Tam LS, Leung YY, Kwok LW, Wong KC, Yu T, et al. Socioeconomic burden of psoriatic arthritis in Hong Kong: direct and indirect costs and the influence of disease pattern. J Rheumatol 2010;37:1214-20.
7. Sokoll KB, Helliwell PS. Comparison of disability and quality of life in rheumatoid and psoriatic arthritis. J Rheumatol 2001;28:1842-6.
8. Kingsley GH, Kowalczyk A, Taylor H, Ibrahim F, Packham JC, McHugh NJ, et al. A randomized placebo-controlled trial of methotrexate in psoriatic arthritis. Rheumatology 2012;51:1368-77.
9. Fraser AD, van Kuijk AW, Westhovens R, Karim Z, Wakefield R, Gerards AH, et al. A randomised, double blind, placebo controlled, multicentre trial of combination therapy with methotrexate plus ciclosporin in patients with active psoriatic arthritis. Ann Rheum Dis 2005;64:859-64.
10. Salvarani C, Macchioni P, Olivieri I, Marchesoni A, Cutolo M, Ferraccioli G, et al. A comparison of cyclosporine, sulfasalazine, and symptomatic therapy in the treatment of psoriatic arthritis. J Rheumatol 2001;28:2274-82.
11. Menter A, Gottlieb A, Feldman SR, Van Voorhees AS, Leonardi CL, Gordon KB, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol 2008;58:826-50.
12. Menter A, Korman NJ, Elmets CA, Feldman SR, Gelfand JM, Gordon KB, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 4. Guidelines of care for the management and treatment of psoriasis with traditional systemic agents. J Am Acad Dermatol 2009;61:451-85.
13. Gniadecki R, Kragballe K, Dam TN, Skov L. Comparison of drug survival rates for adalimumab, etanercept and infliximab in patients with psoriasis vulgaris. Br J Dermatol 2011;164:1091-6.